Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Equity Ratio (2020 - 2025)

Foghorn Therapeutics has reported Equity Ratio over the past 6 years, most recently at 0.55 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.55 for Q4 2025, down 241.63% from a year ago — trailing twelve months through Dec 2025 was 0.55 (down 241.63% YoY), and the annual figure for FY2025 was 0.55, down 241.63%.
  • Equity Ratio for Q4 2025 was 0.55 at Foghorn Therapeutics, down from 0.44 in the prior quarter.
  • Over the last five years, Equity Ratio for FHTX hit a ceiling of 0.54 in Q1 2021 and a floor of 0.55 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.08 (2023), compared with a mean of 0.05.
  • Biggest five-year swings in Equity Ratio: soared 146.49% in 2021 and later plummeted 97696.47% in 2023.
  • Foghorn Therapeutics' Equity Ratio stood at 0.19 in 2021, then tumbled by 99.85% to 0.0 in 2022, then plummeted by 97696.47% to 0.27 in 2023, then skyrocketed by 40.62% to 0.16 in 2024, then crashed by 241.63% to 0.55 in 2025.
  • The last three reported values for Equity Ratio were 0.55 (Q4 2025), 0.44 (Q3 2025), and 0.34 (Q2 2025) per Business Quant data.